These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36946682)

  • 1. A review of the literature: How does prenatal opioid exposure impact placental health and fetal brain development?
    Humphries A; Simcox K; Howell B
    Dev Psychobiol; 2023 Apr; 65(3):e22378. PubMed ID: 36946682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplacental methadone exposure and risk of Neonatal Opioid Withdrawal Syndrome.
    Bhatt-Mehta V; Jing X; Wang X; Zhu HJ
    Pharmacotherapy; 2024 Jan; 44(1):22-27. PubMed ID: 37574548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placental DNA methylation profiles in opioid-exposed pregnancies and associations with the neonatal opioid withdrawal syndrome.
    Radhakrishna U; Vishweswaraiah S; Uppala LV; Szymanska M; Macknis J; Kumar S; Saleem-Rasheed F; Aydas B; Forray A; Muvvala SB; Mishra NK; Guda C; Carey DJ; Metpally RP; Crist RC; Berrettini WH; Bahado-Singh RO
    Genomics; 2021 May; 113(3):1127-1135. PubMed ID: 33711455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome.
    van Hoogdalem MW; Wexelblatt SL; Akinbi HT; Vinks AA; Mizuno T
    Pharmacol Ther; 2022 Jun; 234():108045. PubMed ID: 34813863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placental aromatase expression decreased in severe neonatal opioid withdrawal syndrome.
    Townsel C; Covault JM; Hussain N; Oncken C; Nold C; Campbell WA
    J Matern Fetal Neonatal Med; 2021 Mar; 34(5):670-676. PubMed ID: 31092079
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of neonatal outcomes in pregnant women undergoing medication-assisted treatment of opioid use disorder with methadone or buprenorphine/naloxone.
    Petrich M; Battin M; Walker E; Brown M; Abdelwahab M; Ma'ayeh M; Rood KM
    J Matern Fetal Neonatal Med; 2022 Dec; 35(26):10481-10486. PubMed ID: 36202398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal abstinence syndrome.
    Coyle MG; Brogly SB; Ahmed MS; Patrick SW; Jones HE
    Nat Rev Dis Primers; 2018 Nov; 4(1):47. PubMed ID: 30467370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal opioid use disorder: Placental transcriptome analysis for neonatal opioid withdrawal syndrome.
    Radhakrishna U; Nath SK; Vishweswaraiah S; Uppala LV; Forray A; Muvvala SB; Mishra NK; Southekal S; Guda C; Govindamangalam H; Vargas D; Gardella WG; Crist RC; Berrettini WH; Metpally RP; Bahado-Singh RO
    Genomics; 2021 Nov; 113(6):3610-3617. PubMed ID: 34352367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal Opioid Withdrawal Syndrome (NOWS): A Transgenerational Echo of the Opioid Crisis.
    Weller AE; Crist RC; Reiner BC; Doyle GA; Berrettini WH
    Cold Spring Harb Perspect Med; 2021 Mar; 11(3):. PubMed ID: 32229609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between prenatal opioid exposure, neonatal opioid withdrawal syndrome, and neurodevelopmental and behavioral outcomes at 5-8 months of age.
    Bakhireva LN; Holbrook BD; Shrestha S; Leyva Y; Ashley M; Cano S; Lowe J; Stephen JM; Leeman L
    Early Hum Dev; 2019 Jan; 128():69-76. PubMed ID: 30554024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal and iatrogenic neonatal opioid withdrawal syndrome: Differences and similarities in recognition, management, and consequences.
    Isaac L; van den Hoogen NJ; Habib S; Trang T
    J Neurosci Res; 2022 Jan; 100(1):373-395. PubMed ID: 33675100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the Impact of Prenatal Medication for Opioid Use Disorder on Discharge Home With Parents Among Infants With Neonatal Opioid Withdrawal Syndrome.
    Singleton R; Rutz S; Day G; Hammes M; Wilson AS; Herrick M; Mazut C; Brunner L; Prince J; Desnoyers C; Shaw J; Hirschfeld M; Palis H; Slaunwhite A
    J Addict Med; 2022 Nov-Dec 01; 16(6):e366-e373. PubMed ID: 35245916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Influence of Mediators on the Relationship Between Antenatal Opioid Agonist Exposure and the Severity of Neonatal Opioid Withdrawal Syndrome.
    Devlin LA; Hu Z; Ounpraseuth S; Simon AE; Annett RD; Das A; Fuller JF; Higgins RD; Merhar SL; Smith PB; Crawford MM; Cottrell LE; Czynski AJ; Newman S; Paul DA; Sánchez PJ; Semmens EO; Smith MC; Whalen BL; Snowden JN; Young LW;
    Matern Child Health J; 2023 Jun; 27(6):1030-1042. PubMed ID: 36905529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach. Part II: The clinical application of nonpharmacologic care for NAS/NOWS.
    Velez ML; Jordan C; Jansson LM
    Neurotoxicol Teratol; 2021; 88():107032. PubMed ID: 34600100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach.
    Velez ML; Jordan CJ; Jansson LM
    Neurotoxicol Teratol; 2021; 88():107020. PubMed ID: 34419619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The placenta as a target of opioid drugs†.
    Rosenfeld CS
    Biol Reprod; 2022 Apr; 106(4):676-686. PubMed ID: 35024817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal Opioid Use Disorder and the Risk of Postneonatal Infant Mortality.
    Grossarth S; Osmundson SS; Wiese AD; Phillips SE; Pham A; Leech AA; Patrick SW; Spieker AJ; Grijalva CG; Adgent MA
    JAMA Pediatr; 2023 Jul; 177(7):675-683. PubMed ID: 37155175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. There is reduced immunohistochemical staining of placental aromatase in severe neonatal opioid withdrawal syndrome.
    Townsel C; Odukoya E; Rae J; Thomas D
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):9227-9233. PubMed ID: 34978244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential problems and solutions of opioid-based treatment in neonatal opioid withdrawal syndrome (NOWS): a scoping review protocol.
    Mills-Huffnagle S; Nyland JE
    BMJ Open; 2023 Feb; 13(2):e067883. PubMed ID: 36806065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of
    Bailey BA; Shah DS; Boynewicz KL; Justice NA; Wood DL
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):9383-9390. PubMed ID: 35109759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.